Vitamin D receptor activators.
The fields for clinical employment of vitamin D analogs are growing and under active evaluation in different medical specialties, ranging from dermatology to immunology and oncology. In this review we provide a brief description of the drugs that have been developed more specifically for the treatment of secondary hyperparathyroidism (SH) associated with uremia.
Department of Clinical Science, Sapienza University of Rome and Chair of Nephrology, Sapienza University of Rome, Rome - Italy. sandro.mazzaferro@unirmoma1.it
Sandro
S
Mazzaferro
Marzia
M
Pasquali
Carmina
C
Conte
Giusy
G
Mandanici
Maria
M
Muci
Raffaella
R
Lavini
D002117:Calcitriol / Q000031:analogs & derivatives / Q000627:therapeutic use; D004100:Dihydroxycholecalciferols / Q000627:therapeutic use; D004872:Ergocalciferols / Q000627:therapeutic use; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology; D014511:Uremia / Q000150:complications; D014807:Vitamin D / Q000031:analogs & derivatives*; D005466:Fluorocarbons
D002117:Calcitriol; D004100:Dihydroxycholecalciferols; D004872:Ergocalciferols; D014807:Vitamin D; C042533:1 alpha-hydroxyergocalciferol; C084656:paricalcitol; C040488:26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3; D005466:Fluorocarbons; C521167:2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol